<code id='3DD3C1D2F1'></code><style id='3DD3C1D2F1'></style>
    • <acronym id='3DD3C1D2F1'></acronym>
      <center id='3DD3C1D2F1'><center id='3DD3C1D2F1'><tfoot id='3DD3C1D2F1'></tfoot></center><abbr id='3DD3C1D2F1'><dir id='3DD3C1D2F1'><tfoot id='3DD3C1D2F1'></tfoot><noframes id='3DD3C1D2F1'>

    • <optgroup id='3DD3C1D2F1'><strike id='3DD3C1D2F1'><sup id='3DD3C1D2F1'></sup></strike><code id='3DD3C1D2F1'></code></optgroup>
        1. <b id='3DD3C1D2F1'><label id='3DD3C1D2F1'><select id='3DD3C1D2F1'><dt id='3DD3C1D2F1'><span id='3DD3C1D2F1'></span></dt></select></label></b><u id='3DD3C1D2F1'></u>
          <i id='3DD3C1D2F1'><strike id='3DD3C1D2F1'><tt id='3DD3C1D2F1'><pre id='3DD3C1D2F1'></pre></tt></strike></i>

          
          WSS
          Franklin faces
          Adobe

          Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

          On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

          advertisement

          Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion